Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 3:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 84 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Vehicle topical ocular, eye drops Clear all
Completed Phase 3 Interventional

Assessment of the Safety and Efficacy of BRM421 Ophthalmic Solutions in Dry Eye Subjects.

NCT05695781
View directory record Official record
Conditions
Dry Eye Disease
Interventions
BRM421 Ophthalmic Solution, Vehicle
Drug
Lead sponsor
BRIM Biotechnology Inc.
Industry
Eligibility
18 Years and older
Enrollment
740 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Warwick, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jul 11, 2024 · Synced Oct 2, 2026, 3:23 PM EDT
Completed Phase 2 Interventional Results available

A Study of Safety and Efficacy of UNR844 Chloride (UNR844-Cl) Eye Drops in Subjects With Presbyopia.

NCT03809611
View directory record Official record
Conditions
Presbyopia
Interventions
UNR844-Cl, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
45 Years to 65 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
14
States / cities
Mission Hills, California • Newport Beach, California • Largo, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated May 11, 2022 · Synced Oct 2, 2026, 3:23 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Phase 1/2 Study of AGN-241622 in Healthy Participants and Participants With Presbyopia

NCT04403763
View directory record Official record
Conditions
Presbyopia
Interventions
AGN-241622, Vehicle
Drug
Lead sponsor
AbbVie
Industry
Eligibility
40 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
10
States / cities
Inglewood, California • Los Angeles, California • Mission Hills, California + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2024 · Synced Oct 2, 2026, 3:23 PM EDT
Completed Phase 3 Interventional Results available

Comparing Safety and Efficacy of BOL-303259-X With Timolol Maleate in Subjects With Open-Angle Glaucoma or Ocular Hypertension

NCT01749904
View directory record Official record
Conditions
Open-Angle Glaucoma, Ocular Hypertension
Interventions
BOL-303259-X, Timolol
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Nov 7, 2018 · Synced Oct 2, 2026, 3:23 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Evaluation of Anti-Inflammatory Treatment in Dry Eye Patients

NCT01276223
View directory record Official record
Conditions
Dry Eye Disease
Interventions
Difluprednate 0.05% ophthalmic emulsion, Difluprednate vehicle
Drug · Other
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
722 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Mar 11, 2013 · Synced Oct 2, 2026, 3:23 PM EDT
Completed Phase 2 Interventional

Treatment of Dry Eye Syndrome With Cyclosporin A Eye Drops

NCT00001731
View directory record Official record
Conditions
Keratoconjunctivitis Sicca, Sjogren's Syndrome
Interventions
Cyclosporin A
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 2, 2026, 3:23 PM EDT
Not yet recruiting Phase 3 Interventional

Phase 3, Multi-Center, Randomized, Double-Masked, Placebo-Controlled Study Assessing the Safety and Efficacy of Urcosimod Ophthalmic Solution in Participants With Neuropathic Corneal Pain (NCP).

NCT07838506
View directory record Official record
Conditions
Neuropathic Corneal Pain
Interventions
Urcosimod ophthalmic solution is a preservative-free topical ophthalmic product; supplied in unit dose ampoules; administered QID for 12-weeks., Vehicle Ophthalmic Solution
Drug · Other
Lead sponsor
Okyo Pharma Ltd
Industry
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 2, 2026, 3:23 PM EDT
Completed Phase 3 Interventional Results available

ESSENCE 2: CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)

NCT04523129
View directory record Official record
Conditions
Dry Eye Disease
Interventions
CyclASol topical ocular, eye drops, Vehicle topical ocular, eye drops
Drug
Lead sponsor
Novaliq GmbH
Industry
Eligibility
18 Years and older
Enrollment
834 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
27
States / cities
Phoenix, Arizona • Los Angeles, California • Newport Beach, California + 23 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2023 · Synced Oct 2, 2026, 3:23 PM EDT
Completed Phase 3 Interventional Results available

Study Evaluating the Safety and Efficacy of AR-15512

NCT05285644
View directory record Official record
Conditions
Dry Eye Disease
Interventions
0.003% AR-15512 ophthalmic solution, AR-15512 vehicle ophthalmic solution
Drug
Lead sponsor
Aerie Pharmaceuticals
Industry
Eligibility
30 Years and older
Enrollment
465 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
23
States / cities
Glendale, California • Torrance, California • Colorado Springs, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2025 · Synced Oct 2, 2026, 3:23 PM EDT
Completed Phase 2 Interventional Results available

CyclASol for the Treatment of Moderate to Severe Dry-eye Disease (DED)

NCT02617667
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
Cyclosporine A, Placebo
Drug
Lead sponsor
Novaliq GmbH
Industry
Eligibility
18 Years to 99 Years
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
4
States / cities
Newport Beach, California • Lewiston, Maine • Andover, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2019 · Synced Oct 2, 2026, 3:23 PM EDT
Terminated Phase 3 Interventional Results available

Topical Ophthalmic AGN-195263 for the Treatment of Evaporative Dry Eye

NCT02965846
View directory record Official record
Conditions
Dry Eye Syndromes
Interventions
AGN-195263, Vehicle
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
8
States / cities
Artesia, California • Glendale, California • Chesterfield, Missouri + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2018 · Synced Oct 2, 2026, 3:23 PM EDT
Completed Phase 2Phase 3 Interventional

A Pivotal Safety and Efficacy Study of OCS-01 Eye Drops in Participants With Diabetic Macular Edema (DIAMOND 1)

NCT05066997
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Dexamethasone ophthalmic suspension (OCS-01), Vehicle
Drug
Lead sponsor
Oculis
Industry
Eligibility
18 Years to 85 Years
Enrollment
552 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
40
States / cities
Phoenix, Arizona • Springdale, Arkansas • Beverly Hills, California + 35 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 2, 2026, 3:23 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Topical Bromfenac Ophthalmic Solution vs. Placebo in Subjects With Allergic Conjunctivitis

NCT00423007
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
Bromfenac, Placebo
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
10 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Mar 14, 2013 · Synced Oct 2, 2026, 3:23 PM EDT
Completed Phase 2 Interventional Results available

Phase 2: VVN461 Ophthalmic Solution for Post -Operative Ocular Inflammation After Cataract Surgery

NCT06164743
View directory record Official record
Conditions
Inflammation
Interventions
VVN461 Ophthalmic Solution 1.0%, VVN461 Ophthalmic Solution 0.5%, Vehicle
Drug
Lead sponsor
VivaVision Biotech, Inc
Industry
Eligibility
21 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
10
States / cities
Inglewood, California • Petaluma, California • Rancho Cordova, California + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 2, 2026, 3:23 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Efficient Study of ACULAR in Inhibiting Proliferative Retinopathy in Prematurity

NCT00634972
View directory record Official record
Conditions
Retinopathy of Prematurity, Retinal Detachment, Blindness
Interventions
ACULAR, REFRESH TEARS, placebo
Drug
Lead sponsor
University of South Alabama
Other
Eligibility
10 Days to 15 Days
Enrollment
83 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Mobile, Alabama
Source: ClinicalTrials.gov public record
Updated Dec 8, 2020 · Synced Oct 2, 2026, 3:23 PM EDT
Completed Phase 3 Interventional

Steroids and Cross-linking for Ulcer Treatment

NCT04097730
View directory record Official record
Conditions
Keratitis Bacterial
Interventions
Moxifloxacin Ophthalmic, Difluprednate Ophthalmic, Riboflavin Ophthalmic, Topical Placebo
Drug · Other
Lead sponsor
Thomas M. Lietman
Other
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
San Francisco, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 2, 2026, 3:23 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Efficacy of SDP-4 in Subjects With Dry Eye Disease (DED) (SDP-4-CS202)

NCT04535947
View directory record Official record
Conditions
Dry Eye
Interventions
Vehicle, SDP-4 Ophthalmic Solution (1.0%)
Drug
Lead sponsor
Silk Technologies, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
5
States / cities
Garden Grove, California • Murrieta, California • Newport Beach, California + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2022 · Synced Oct 2, 2026, 3:23 PM EDT
Completed Phase 2Phase 3 Interventional Results available

CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease (DED)

NCT03292809
View directory record Official record
Conditions
Dry Eye Disease
Interventions
CyclASol topical ocular, eye drops, Vehicle topical ocular, eye drops
Drug
Lead sponsor
Novaliq GmbH
Industry
Eligibility
18 Years and older
Enrollment
328 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
9
States / cities
Newport Beach, California • Torrance, California • Indianapolis, Indiana + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2022 · Synced Oct 2, 2026, 3:23 PM EDT
Recruiting Phase 2 Interventional

An Exploratory Efficacy and Safety Study of DFL24498 Topical Ophthalmic Solution Compared With Vehicle in Participants With Dry Eye Disease

NCT07503886
View directory record Official record
Conditions
Dry Eye Disease (DED)
Interventions
DFL24498, Vehicle
Drug · Other
Lead sponsor
Dompé Farmaceutici S.p.A
Industry
Eligibility
18 Years and older
Enrollment
417 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
24
States / cities
Chandler, Arizona • Azusa, California • Glendale, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 2, 2026, 3:23 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Safety and Efficacy of BRM421 for Dry Eye Syndrome Treatment

NCT04343287
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
BRM421, Placebo
Drug
Lead sponsor
BRIM Biotechnology Inc.
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
4
States / cities
Newport Beach, California • Indianapolis, Indiana • Andover, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 2, 2026, 3:23 PM EDT
Completed Phase 3 Interventional Results available

The Safety and Efficacy of SYD-101 in Children With Myopia

NCT03918915
View directory record Official record
Conditions
Nearsightedness, Near Sightedness, Near-sightedness
Interventions
SYD-101 0.01%, SYD-101 0.03%, Vehicle
Drug
Lead sponsor
Sydnexis, Inc.
Industry
Eligibility
3 Years to 14 Years
Enrollment
852 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
41
States / cities
Irwindale, California • Pasadena, California • San Diego, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 2, 2026, 3:23 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Nyxol With Pilocarpine Eye Drops in Subjects With Presbyopia

NCT04675151
View directory record Official record
Conditions
Presbyopia
Interventions
Phentolamine Ophthalmic Solution 0.75%, Pilocarpine, Placebo
Drug · Other
Lead sponsor
Ocuphire Pharma, Inc.
Industry
Eligibility
40 Years to 64 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
17
States / cities
Laguna Hills, California • Newport Beach, California • Crystal River, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2025 · Synced Oct 2, 2026, 3:23 PM EDT
Completed Phase 2 Interventional Results available

A Research Study To See How Well an Eye Drop, SURF-100 (A Mycophenolic Acid/Betamethasone Sodium Phosphate Combination), Works and What Side Effects There Are in Subjects With Dry Eye Disease

NCT04734197
View directory record Official record
Conditions
Dry Eye Disease
Interventions
SURF-100 (Combination of 0.3% Mycophenolic Acid and 0.01% Betamethasone Sodium Phosphate), Mycophenolic Acid 0.1%, Mycophenolic Acid 0.3%, Betamethasone Sodium Phosphate 0.01%, Placebo Comparator: Vehicle, Cyclosporine 0.05% Ophthalmic Emulsion, Lifitegrast 5% Ophthalmic Solution
Drug
Lead sponsor
Surface Ophthalmics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
349 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
40
States / cities
Phoenix, Arizona • Azusa, California • Hemet, California + 33 more
Source: ClinicalTrials.gov public record
Updated May 11, 2025 · Synced Oct 2, 2026, 3:23 PM EDT
Completed Phase 2 Interventional Results available

Research Study To See How Well An Eye Drop (SURF-200) Works, What Side Effects There Are, And To Compare It With Vehicle In Subjects With An Episodic Flare-Up of Dry Eye Disease

NCT04734210
View directory record Official record
Conditions
Dry Eye Disease
Interventions
0.02% Betamethasone Sodium Phosphate, 0.04% Betamethasone Sodium Phosphate, Placebo
Drug
Lead sponsor
Surface Ophthalmics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
28
States / cities
Dothan, Alabama • Azusa, California • Mission Hills, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Oct 2, 2026, 3:23 PM EDT